Drugs Made In America Acquisition II Corp. (DMII)

NASDAQ: DMII · Real-Time Price · USD
10.02
-0.01 (-0.10%)
Dec 5, 2025, 4:00 PM EST - Market closed
Market Cap 505.86M
Revenue (ttm) n/a
Net Income (ttm) -455,157
Shares Out 51.20M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,739
Open 10.02
Previous Close 10.03
Day's Range 10.02 - 10.03
52-Week Range 9.94 - 10.06
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About DMII

Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida. [Read more]

Industry Shell Companies
Sector Financials
IPO Date Sep 25, 2025
Country United States
Stock Exchange NASDAQ
Ticker Symbol DMII
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

U.S. IPO Weekly Recap: One Small Debut As More Names Join The Pipeline

One IPO and four SPACS debuted this week. Six IPOs and three SPACs submitted initial filings. Two sizable deals are currently scheduled to price in the week ahead as the 3Q IPO market comes to a close...

Other symbols: AEXACBKFRMIHWEPMGNNP
2 months ago - Seeking Alpha

Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering

Fort Lauderdale, FL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) (the “Company”) today announced that it closed its initial public offering of 50,000,...

2 months ago - GlobeNewsWire

Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

Drugs Made In America Acquisition II (Nasdaq: DMIIU) announced today the pricing yesterday of its initial public offering of 50,000,000 units at $10.00 per unit.

2 months ago - GLOBE NEWSWIRE

SPAC Drugs Made In America Acquisition II files for a $500 million IPO, targeting pharmaceuticals

Drugs Made In America Acquisition II, a blank check company targeting the pharmaceutical industry, filed on Monday with the SEC to raise up to $500 million in an initial public offering.

4 months ago - Renaissance Capital

Drugs Made In America Acquisition II IPO Registration Document (S-1)

Drugs Made In America Acquisition II has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC